This study provides the novel findings that antagonism of the glucagon’s actions, using a pharmacological inhibitor of the glucagon receptor, enhances cardiac function in the post-MI heart and limits adverse cardiac remodelling. This evidence concerns the gene GCG and myocardial infarction.